2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Sunday, November 8, 2015

4:30PM-6:00PM: Abstract Number: 1026

Microrna-125a-5p Has Increased Expression in Active Systemic Juvenile Idiopathic Arthritis and Is an Essential Modulator of Regulatory Macrophage Phenotypes in Vitro

Pediatric Rheumatology - Pathogenesis and Genetic

4:30PM-6:00PM: Abstract Number: 1080

Modified Rodnan Skin Score Thresholds for the Optimization of Cohort Enrichment in Clinical Trials in Skin Fibrosis in Patients with Diffuse Cutaneous Systemic Sclerosis

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's - Clinical Aspects and Therapeutics I

4:30PM-6:00PM: Abstract Number: 1008

Morphometric Study of Algerian Hips: An Etiological Study to Explain the Low Prevalence of Hip Osteoarthritis in Algeria

Osteoarthritis - Clinical Aspects I: Imaging and Epidemiology

4:30PM-6:00PM: Abstract Number: 1083

Nationwide Trends in Hospitalization and in-Hospital Mortality Associated with Granulomatosis with Polyangiitis (GPA)

Vasculitis I

4:30PM-6:00PM: Abstract Number: 1033

Novel Ligand-Independent Peptide Inhibitors of Triggering Receptor Expressed on Myeloid Cells 1 (TREM-1) and T Cell Receptor (TCR): Efficacy in a Collagen-Induced Arthritis Model Suggests New Targeted Treatment for Rheumatoid Arthritis

Rheumatoid Arthritis - Animal Models I

4:30PM-6:00PM: Abstract Number: 1021

Nucleic Acids Sensing Receptors RIG-I and MDA5 As Potential Amplifiers of the Interferon Signature in Childhood Onset Systemic Lupus Erythematosus

Pediatric Rheumatology - Pathogenesis and Genetic

4:30PM-6:00PM: Abstract Number: 1061

Patients with Fibromyalgia (FM) Do Not Fulfill Classification Criteria for Axial Spondyloarthritis (axSpA) but Patients with Axspa May Fulfill Classification Criteria for FM

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Clinical Aspects and CoMorbidities

4:30PM-6:00PM: Abstract Number: 1053

Phosphatidylinositol-3-Kinase Delta Pathway a Novel Therapeutic Target for Sjogren’s Syndrome

Sjögren's Syndrome I: Basic Insights

4:30PM-6:00PM: Abstract Number: 1042

Pragmatic Multicenter Open-Label Randomized Controlled Trial of Stopping TNF-Inhibitors in Rheumatoid Arthritis Patients in Remission or Stable Low Disease Activity in the Netherlands

Rheumatoid Arthritis - Clinical Aspects I - Treatment Advances and Strategies

4:30PM-6:00PM: Abstract Number: 1062

Predictive Validity of the ASAS-Classification Criteria for Axial and Peripheral Spondyloarthritis – a Final Analysis

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Clinical Aspects and CoMorbidities

4:30PM-6:00PM: Abstract Number: 1004

Prevalence and Cross-Sectional Risk Factors of Ankle Osteoarthritis in a Community-Based Cohort

Osteoarthritis - Clinical Aspects I: Imaging and Epidemiology

4:30PM-6:00PM: Abstract Number: 1058

Prevalence of Comorbidities in Spondyloarthritis and Evaluation of Their Monitoring: Results of the International Cross-Sectional ASAS-Comospa Study

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Clinical Aspects and CoMorbidities

4:30PM-6:00PM: Abstract Number: 1046

Previous Biologic Disease-Modifying Antirheumatic Drug (bDMARD) Exposure and Efficacy and Safety Analysis from a Phase 3 Study of Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitors

Rheumatoid Arthritis-Small Molecules, Biologics and Gene Therapy II: Small Molecular Targeted Therapies

4:30PM-6:00PM: Abstract Number: 1009

Promoting Professional Development of Medical Educators in Rheumatology: Perspectives of Clinician Scholar Educators

Education

4:30PM-6:00PM: Abstract Number: 1031

Quantifying the Delays to Rheumatologist Consultation and Treatment Among Patients with Systemic Inflammatory Rheumatic Diseases

Quality Measures and Quality of Care

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].